CTIS2023-508736-62-00进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction - CRD-750-201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Is an adult male or female patient 18 years of age or older, at the time of Screening, Has evidence in the medical history supporting a diagnosis of clinical heart failure (HF) syndrome, NYHA functional class II to III, with the duration of at least 6 months prior to the time of Screening, Has ejection fraction (EF) = 40% % by transthoracic echocardiogram (TTE) performed and interpreted locally at the time of Screening, Has NT-proBNP level =600 pg/ml at the time of Screening. Patients with atrial fibrillation or flutter at the time of Screening are required to have an NT-proBNP level =1000 pg/mL at the time of Screening, Is on stable optimized doses of guideline-directed HF therapy for a minimum of 4 weeks prior to the time of Screening, and during the Screening Period, with no planned changes after randomization, Has had no addition of new guideline-directed HF therapy (with the exception of diuretics) within the 3 months prior to the time of Screening or during the Screening Period, Other protocol-defined criteria apply
排除标准
- •Has documented EF =40% by TTE within 6 months of the time of Screening or during the Screening Period, Has the presence of or plan for mechanical circulatory support, Has any of the following findings at Screening: oA clinically significant abnormal finding on ECG considered by the Investigator to pose a risk to the safety of the patient; AND/OR oA QTcF interval of >500 msec AND/OR oA family history of Long QT Syndrome AND/OR oUtilization of concomitant therapies known to increase the risk of torsade de pointes, Other protocol-defined criteria apply, Has known bleeding diathesis, Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 60 days of the time of Screening or during the Screening Period, Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, diuretics) or routinely scheduled ultrafiltration, Has any clinically significant abnormal findings on physical examination as judged by the Investigator (or designee), AND/OR vital signs recorded at Screening of the following: o Average systolic blood pressure after a triplicate recording of <90 mmHg or =180 mmHg; o Average diastolic blood pressure after a triplicate recording of =90 mmHg; or o Heart rate <45 or >90 beats per minute., Has elective interventions (eg, percutaneous coronary intervention, device implantation, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study, Has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid, or other major cardiovascular surgery or carotid angioplasty within 60 days of the time of Screening or during the Screening Period, Has clinical suspicion of infiltrative cardiomyopathy (eg, amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease, Has had prior or planned orthotopic heart transplantation
研究者
相似试验
进行中（未招募）
1 期
Clinical trial in subjects with advanced Hepatocellular Carcinoma and Child Pugh B cirrhosisAdvanced Hepatocellular CarcinomaMedDRA version: 19.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000489-23-BGCan-Fite BioPharma Ltd.78
进行中（未招募）
1 期
An investigational study to assess the safety and efficacy of a new investigational drug in subjects with Non-Alcoholic Steatohepatitis (NASH)onalcoholic steatohepatitis (NASH)MedDRA version: 20.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002496-10-ATGilead Sciences, Inc.125
进行中（未招募）
1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe HypertriglyceridemiaSevere Hypertriglyceridemia (SHTG)MedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2020-000641-13-PL89bio, Inc.90
进行中（未招募）
1 期
Study of ASN100 in Ventilated SubjectsPrevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated SubjectsEUCTR2016-002146-23-PLArsanis, Inc.354
进行中（未招募）
1 期
A study to investigate the safety and effectiveness of treatment with the drug APD334 in patients with ulcerative colitis (a form of inflammatory bowel disease)lcerative colitisMedDRA version: 18.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2015-001942-28-ESArena Pharmaceuticals, Inc.240